Talisman Therapeutics Limited, Babraham Research Campus, Cambridge CB22 3AT, UK.
Independent Consultant, Hitchin, UK.
Drug Discov Today. 2021 Nov;26(11):2489-2495. doi: 10.1016/j.drudis.2021.05.001. Epub 2021 May 18.
Spiralling research costs combined with urgent pressures from the Coronavirus 2019 (COVID-19) pandemic and the consequences of climate disruption are forcing changes in drug discovery. Increasing the predictive power of in vitro human assays and using them earlier in discovery would refocus resources on more successful research strategies and reduce animal studies. Increasing laboratory automation enables effective social distancing for researchers, while allowing integrated data capture from remote laboratory networks. Such disruptive changes would not only enable more cost-effective drug discovery, but could also reduce the overall carbon footprint of discovering new drugs.
螺旋式上升的研究成本，加上 2019 年冠状病毒病（COVID-19）大流行的紧迫压力和气候破坏的后果，正在迫使药物发现发生变化。提高体外人体检测的预测能力，并在发现阶段更早地使用这些检测，将重新调整资源，以支持更成功的研究策略，并减少动物研究。增加实验室自动化，使研究人员能够有效保持社交距离，同时允许从远程实验室网络捕获集成数据。这种颠覆性的变化不仅能够实现更具成本效益的药物发现，还可以减少发现新药的总体碳足迹。
